Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function.
Azza Abdel-GadirL SchneiderA CasiniL-M CharbonnierS V LittleT HarringtonD T UmetsuR RachidTalal A ChatilaPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2018)
OIT supplemented by omalizumab promotes allergen desensitization through an initial omalizumab-dependent step that acutely depletes allergen-reactive T cells, followed by an increase in allergen-specific Treg cell activity due to the reversal of their Th2 cell-like programme. Improved Treg cell function may be a key mechanism by which OIT ameliorates food allergy.